Supplementary Tables S1-S22 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Table S1. Prior Therapy Eligibility Criteria for Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion (Part 2) and Patients Treated With Linrodostat Mesylate Plus Nivolumab and Ipilimumab (Part 3) Supplementary Table S2. Baseline Characteristics of and Prior Therapies in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation Supplementary Table S3. Baseline Characteristics of and Prior Therapies in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion Supplementary Table S4. Baseline Characteristics of and Prior Therapies in Patients Treated With Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S5. Representativeness of Study Participants Supplementary Table S6. Exposure and Disposition in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation and Clinical Pharmacology Substudies Supplementary Table S7. Exposure and Disposition in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion Supplementary Table S8. Exposure and Disposition in Patients Treated With Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S9. Safety Summary for Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation Supplementary Table S10. Liver- and Thyroid-Related Laboratory Abnormalitiesa Reported in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation Supplementary Table S11. Safety Summary for Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion and Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S12. All-Cause AEs Reported in >15% of Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion Supplementary Table S13. Immune-Related AEs Reported in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation and Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S14. Liver- and Thyroid-Related Laboratory Abnormalitiesa Reported in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation and Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S15. All-Cause AEs Reported in >15% of Patients Treated With Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S16. Antitumor Activity per Investigator Review in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation Supplementary Table S17. Antitumor Activity per Investigator Review in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion Supplementary Table S18. Antitumor Activity per Investigator Review in Patients Treated With Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S19. Response per Investigator Review by PD-L1 Status in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation Supplementary Table S20. Response per Investigator Review by PD-L1 Status in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion Supplementary Table S21. Response per Investigator Review by PD-L1 Status in Patients Treated With Linrodostat Mesylate Plus Nivolumab Plus Ipilimumab Supplementary Table S22. Comparison of Baseline Characteristics of and Prior Therapies in All Patients Treated With Linrodostat Mesylate Plus Nivolumab Versus Those in Patients in the Biomarker Cohort
Authors: Jason J. Luke, Karen Gelmon, Lillian L. Siu, Victor Moreno, Jayesh Desai, Carlos A. Gomez-Roca, Matteo S. Carlino, Russell K. Pachynski, Rasha Cosman, Quincy Siu-Chung Chu, Silvia Damian, Giuseppe Curigliano, Rachel Tam, Xianling Wang, Chandrika Jeyamohan, Lily Wang, Li Zhu, Julia Santucci-Pereira, Danielle M. Greenawalt, Josep Tabernero
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4411003449